Innovating Sarcomere-Directed Potential Medicines
scientists working in a laboratory


As a pioneer in muscle biology and the mechanics of muscle, we have developed a broad and diverse pipeline of cardiovascular and neuromuscular muscle-directed medicines with the potential to improve muscle function in diseases of impaired contractility.

Clinical Trials

At Cytokinetics we are committed to rigorous research to elaborate on the safety and efficacy of our potential medicines. Over our 25-year history, we have conducted more than 100 clinical trials in partnership with hundreds of research institutions across the world, and are grateful to the tens of thousands of patients who have contributed to our development programs.

heart failure icon

Conducted 30+ clinical trials to assess the efficacy and safety of omecamtiv mecarbil in patients with heart failure with a reduced ejection fraction.

Heart Failure clinical trials

hcm disease icon

Evaluating the efficacy and safety of aficamten in a broad and expansive clinical trial program spanning obstructive and non-obstructive hypertrophic cardiomyopathy.

HCM clinical trials

amyotrophic lateral sclerosis icon

Conducted some of the largest clinical trials in ALS, culminating in the Phase 3 clinical trial, COURAGE-ALS.

ALS clinical trials

All drug candidates are investigational and are not approved by any regulatory agency. Their safety and effectiveness have not been established.


March 2023
Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
March 2023
Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)
February 2023
Preclinical Characterization of CK-4021586, a New Class of Cardiac Myosin Inhibitors for the Treatment of Hypertrophic Cardiomyopathy